Cetuximab-Associated Crescentic Diffuse Proliferative Glomerulonephritis

Table 1

Patient’s sodium (mmol/l), potassium (mmol/l), BUN (mg/dl), creatinine (mg/dl), serum albumin (gm/dl), proteinuria (mg/dl), and hematuria (per hpf) during 7 cycles of cetuximab treatment and 3 weeks later after completing 7th cycle of treatment.

	1st cycle	2nd cycle	3rd cycle	4th; cycle	5th; cycle	6th; cycle	7th; cycle	3 weeks later
Sodium	130	133	133	136	133	130	131	134
Potassium	4.5	4.9	4.4	4.6	4.4	4.5	4.3	4.1
BUN	20	24	25	30	19	19	18	100
Creatinine	0.8	0.7	0.7	0.7	0.7	0.8	0.8	6.6
Serum albumin	3.2	3.7	3.5	3.3	3.0	3.1	2.4	1.5
Proteinuria	30	n/a	n/a	n/a	n/a	n/a	n/a	>500
Hematuria	1	n/a	n/a	n/a	n/a	n/a	n/a	81